CYP17 inhibitors - Abiraterone, C17,20-lyase inhibitors and multi-targeting agents

Nature Reviews Urology

Volumn 11, Issue 1, 2014, Pages 32-42

  Yin, Lina ^a   Hu, Qingzhong ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; ABIRATERONE ACETATE; ANDROGEN; ANDROGEN RECEPTOR; CYTOCHROME P450 17; DOCETAXEL; GALETERONE; KETOCONAZOLE; ORTERONEL; PREDNISONE; STEROID; STEROID 17ALPHA MONOOXYGENASE; UNCLASSIFIED DRUG; VT 464;

ANDROGEN SYNTHESIS; CANCER SURVIVAL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG USE; ENZYME ACTIVITY; ENZYME INHIBITION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW;

ANDROSTENOLS; ENZYME INHIBITORS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; TUMOR MARKERS, BIOLOGICAL;

EID: 84893720016     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2013.274     Document Type: Review

References (91)

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. CA Cancer J. Clin. 62, 10-29 (2012).
2. van Leeuwen, P. J. et al. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur. J. Cancer 46, 377-383 (2010).
3. Siegel, R. et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62, 220-241 (2012).
4. Welch, H. G. & Albertsen, P. C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J. Natl Cancer Inst. 101, 1325-1329 (2009).
5. Holmberg, L. et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N. Engl. J. Med. 347, 781-789 (2002).
6. Parker, C. Active surveillance: towards a new paradigm in the management of early prostate cancer. Lancet Oncol. 5, 101-106 (2004).
7. Bannuru, R. R. et al. Comparative evaluation of radiation treatments for clinically localized prostate cancer: an updated systematic review. Ann. Intern. Med. 155, 171-178 (2011).
8. Meng, M. V. in Current Medical Diagnosis and Treatment 2013 (eds Papadakis, M. A., McPhee, S. J. & Rabow, M. W.) 1630-1638 (The McGraw-Hill Medical, 2013).
9. Geller, J. Basis for hormonal management of advanced prostate cancer. Cancer 71 (Suppl. 3), 1039-1045 (1993).
10. Imamoto, T. et al. The role of testosterone in the pathogenesis of prostate cancer. Int. J. Urol. 15, 472-480 (2008).
11. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
12. Nilsson, S. et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 8, 587-589 (2007).
13. Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813-822 (2011).
14. Yin, L., Hu, Q. & Hartmann, R. W. Recent progress in pharmaceutical therapies for castration-resistant prostate cancer. Int. J. Mol. Sci. 14, 13958-13978 (2013).
15. Franchimont, P. Regulation of gonadal androgen secretion. Horm. Res. 18, 7-17 (1983).
16. Rainey, W. E. & Nakamura, Y. Regulation of the adrenal androgen biosynthesis. J. Steroid. Biochem. Mol. Biol. 108, 281-286 (2008).
17. Bolton, E. C. et al. Cell-and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev. 21, 2005-2017 (2007).
18. Zhu, M. L. & Kyprianou, N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr. Relat. Cancer 15, 841-849 (2008).
19. Migliaccio, A. et al. Steroid-induced androgen receptor-oestradiol receptor β-Src complex triggers prostate cancer cell proliferation. EMBO J. 19, 5406-5417 (2000).
20. Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B. & Mohler, J. L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 11, 4653-4657 (2005).
21. Suzuki, H. et al. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 29, 153-158 (1996).
22. Hara, T. et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 63, 149-153 (2003).
23. Zhao, X. Y. et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. 6, 703-706 (2000).
24. Cai, C. et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 71, 6503-6513 (2011).
25. Montgomery, R. B. et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68, 4447-4454 (2008).
26. Chang, K. H. et al. Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc. Natl Acad. Sci. USA 108, 13728-13733 (2011).
27. Mohler, J. L., Titus, M. A. & Wilson, E. M. Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone. Clin. Cancer Res. 17, 5844-5849 (2011).
28. Small, E. J., Baron, A. D., Fippin, L. & Apodaca, D. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J. Urol. 157, 1204-1207 (1997).
29. Attard, G. et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 26, 4563-4571 (2008).
30. DeVore, N. M. & Scott, E. E. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001. Nature 482, 116-120 (2012).
31. Hu, Q., Negri, M., Olgen, S. & Hartmann, R. W. The role of fluorine substitution in biphenyl methylene imidazole type CYP17 inhibitors for the treatment of prostate carcinoma. Chem. Med. Chem. 5, 899-910 (2010).
32. Hu, Q., Yin, L., Jagusch, C., Hille, U. E. & Hartmann, R. W. Isopropylidene substitution increases activity and selectivity of biphenyl methylene 4-pyridine type CYP17 inhibitors. J. Med. Chem. 53, 5049-5053 (2010).
33. Hu, Q. et al. Synthesis, biological evaluation, and molecular modeling studies of methylene imidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17) - part II: core rigidification and influence of substituents at the methylene bridge. Bioorg. Med. Chem. 16, 7715-7727 (2008).
34. Hille, U. E. et al. Novel CYP17 inhibitors: synthesis, biological evaluation, structure-activity relationships and modelling of methoxy-and hydroxy-substituted methyleneimidazolyl biphenyls. Eur. J. Med. Chem. 44, 2765-2775 (2009).
35. Pinto-Bazurco Mendieta, M. A. et al. CYP17 inhibitors. Annulations of additional rings in methylene imidazole substituted biphenyls: synthesis, biological evaluation and molecular modelling. Arch. Pharm. (Weinheim) 341, 597-609 (2008).
36. Jagusch, C. et al. Synthesis, biological evaluation and molecular modelling studies of methyleneimidazole substituted biaryls as inhibitors of human 17α-hydroxylase-17,20-lyase (CYP17). Part I: heterocyclic modifications of the core structure. Bioorg. Med. Chem. 16, 1992-2010 (2008).
37. Abadi, A. H., Abou-Seri, S. M., Hu, Q., Negri, M. & Hartmann, R. W. Synthesis and biological evaluation of imidazolylmethylacridones as cytochrome P-450 enzymes inhibitors. Med. Chem. Comm. 3, 663-666 (2012).
38. Hille, U. E. et al. Steroidogenic cytochrome P450 (CYP) enzymes as drug targets: combining substructures of known CYP inhibitors leads to compounds with different inhibitory profile. C. R. Chim. 12, 1117-1126 (2009).
39. Yin, L. & Hu, Q. Drug discovery for breast cancer and coinstantaneous cardiovascular disease: what is the future? Future Med. Chem. 5, 359-362 (2013).
40. Yin, L. et al. Novel imidazol-1-ylmethyl substituted 1,2,5,6- tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome. J. Med. Chem. 55, 6629-6633 (2012).
41. Emmerich, J., Hu, Q., Hanke, N. & Hartmann, R. W. Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type. J. Med. Chem. 56, 6022-6032 (2013).
42. Gobbi, S. et al. Modulation of cytochromes P450 with xanthone-based molecules: from aromatase to aldosterone synthase and steroid 1β-hydroxylase inhibition. J. Med. Chem. 56, 1723-1729 (2013).
43. Yin, L., Hu, Q. & Hartmann, R. W. 3-Pyridinyl substituted aliphatic cycles as CYP11B2 inhibitors: aromaticity abolishment of the core significantly increased selectivity over CYP1A2. PLoS ONE 7, e48048 (2012).
44. Hu, Q., Yin, L. & Hartmann, R. W. Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer. J. Med. Chem. 55, 7080-7089 (2012).
45. Yin, L., Hu, Q. & Hartmann, R. W. Tetrahydropyrroloquinolinone type dual inhibitors of aromatase/aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks. J. Med. Chem. 56, 460-470 (2013).
46. Jarman, M., Barrie, S. E. & Llera, J. M. The 16,17-double bond is needed for irreversible inhibition of human cytochrome P45017α by abiraterone (17-(3-pyridyl)androsta-5,16-dien-3β-ol) and related steroidal inhibitors. J. Med. Chem. 41, 5375-5381 (1998).
47. Janseen. Highlights of prescribing information: Zytiga® [online], http://www.zytigahcp. com/pdf/full-prescribing-info.pdf (2013).
48. Ryan, C. J. et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J. Clin. Oncol. 28, 1481-1488 (2010).
49. Acharya, M. et al. A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. Xenobiotica 43, 379-389 (2013).
50. O'Donnell, A. et al. Hormonal impact of the 17α-hydroxylase/C(17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br. J. Cancer 90, 2317-2325 (2004).
51. Tannock, I. et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J. Clin. Oncol. 7, 590-597 (1989).
52. Attard, G. et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 27, 3742-3748 (2009).
53. Ryan, C. J. et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin. Cancer Res. 17, 4854-4861 (2011).
54. Danila, D. C. et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J. Clin. Oncol. 28, 1496-1501 (2010).
55. Reid, A. H. et al. Significant and sustained antitumor activity in postdocetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J. Clin. Oncol. 28, 1489-1495 (2010).
56. Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138-148 (2013).
57. Logothetis, C. J. et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol. 13, 1210-1217 (2012).
58. Sternberg, C. N. et al. Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann. Oncol. 24, 1017-1025 (2013).
59. Efstathiou, E. et al. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J. Clin. Oncol. 30, 637-643 (2012).
60. US National Library of Medicine. ClinicalTrials. gov [online], http://www.clinicaltrial. gov/ct2/show/NCT00638690 (2013).
61. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
62. Fizazi, K. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13, 983-992 (2012).
63. US National Library of Medicine. ClinicalTrials. gov [online], http://www.clinicaltrial. gov/ct2/show/NCT00887198 (2013).
64. Small, E. J. et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J. Clin. Oncol. 22, 1025-1033 (2004).
65. Eisner, J. R. et al. Assessment of steroid hormones upstream of P450c17 (CYP17) in chemically castrate male rhesus monkeys following treatment with the CYP17 inhibitors VT-464 and abiraterone acetate (AA) [abstract]. Endocr. Rev. 33 (03-MeetingAbstracts), SAT-266 (2012).
66. Potter, G. A., Barrie, S. E., Jarman, M. & Rowlands, M. G. Novel steroidal inhibitors of human cytochrome P450 17α-hydroxylase-C17,20- lyase): potential agents for the treatment of prostatic cancer. J. Med. Chem. 38, 2463-2471 (1995).
67. Li, R. et al. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin. Cancer Res. 18, 3571-3579 (2012).
68. Soifer, H. S. et al. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J. Biol. Chem. 287, 3777-3787 (2012).
69. Yamaoka, M. et al. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. J. Steroid Biochem. Mol. Biol. 129, 115-128 (2012).
70. Kaku, T. et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg. Med. Chem. 19, 6383-6399 (2011).
71. Dreicer, R. et al. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I/II, open-label study [abstract 3084]. J. Clin. Oncol. 28 (Suppl. 15), a3084 (2010).
72. Agus, D. B. et al. Safety, efficacy, and pharmacodynamics of the investigational agent orteronel (TAK-700) in metastatic castration-resistant prostate cancer (mCRPC): updated data from a phase I/II study [abstract 98]. J. Clin. Oncol. 30 (Suppl. 5), a98 (2012).
73. George, D. J. et al. Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): updated results of a phase II study [abstract 4549]. J. Clin. Oncol. 30 (Suppl. 5), a4549 (2012).
74. Dreicer, R. et al. A phase III, randomized, double-blind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy [abstract TPS4693]. J. Clin. Oncol. 30 (Suppl. 15), aTPS4693 (2012).
75. Eisner, J. R. et al. VT-464: a novel, selective inhibitor of P450c17(CYP17)-17,20 lyase for castration-refractory prostate cancer (CRPC) [abstract 198]. J. Clin. Oncol. 30 (Suppl. 5), a198 (2012).
76. Abbott, D. H. et al. Plasma steroid concentrations in male rhesus monkeys following treatment with the P450c17 (CYP17) inhibitors VT-464 and abiraterone acetate: a comparison to human 17,20-Lyase (lyase) and combined lyase/17α-hydroxylase (hydroxylase) deficiencies [abstract]. Endocr. Rev. 33 (03-MeetingAbstracts), SAT-256 (2012).
77. Pisle, S. T. et al. Activity of VT-464, a selective CYP17 lyase inhibitor, in the LNCaP prostate cancer xenograft model [abstract 64]. J. Clin. Oncol. 30 (Suppl. 5), a64 (2012).
78. European Medicines Agency. ClinicalTrialsRegister. eu [online], https://www.clinicaltrialsregister. eu/ctr-search/search?query=2011-004103-20 (2013).
79. Mostaghel, E. A. et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin. Cancer Res. 17, 5913-5925 (2011).
80. Handratta, V. D. et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J. Med. Chem. 48, 2972-2984 (2005).
81. Vasaitis, T. et al. Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitor VN/124-1 in prostate cancer. Mol. Cancer Ther. 7, 2348-2357 (2008).
82. Bruno, R., Gover, T., Burger, A., Brodie, A. M. H. & Njar, V. C. O. 17α-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen independent prostate cancer cells via induction of the endoplasmic reticulum stress response. Mol. Cancer Ther. 7, 2828-2836 (2008).
83. Bruno, R. D. et al. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids 76, 1268-1279 (2011).
84. American Association for Cancer Research. Early clinical data show galeterone safe, effective against prostate cancer [online], http://www.aacr.org/home/public-media/aacr-press-releases. aspx?d=2769 (2012).
85. US National Library of Medicine. ClinicalTrials. gov [online], http://www.clinicaltrial. gov/ct2/show/NCT01709734 (2013).
86. Dutt, S. S. & Gao, A. C. Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol. 5, 1403-1413 (2009).
87. Hu, Q., Jagusch, C., Hille, U. E., Haupenthal, J. & Hartmann, R. W. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer. J. Med. Chem. 53, 5749-5758 (2010).
88. Pinto-Bazurco Mendieta, M. A., Hu, Q., Engel, M. & Hartmann, R. W. Highly potent and selective non-steroidal dual inhibitors of CYP17/CYP11B2 for the treatment of prostate cancer to reduce risks of cardiovascular diseases. J. Med. Chem. 56, 6101-6107 (2013).
89. Efstathiou, J. A. et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J. Clin. Oncol. 27, 92-99 (2008).
90. US National Library of Medicine. ClinicalTrials. gov [online], http://clinicaltrials. gov/show/NCT01647789 (2013).
91. Hu, Q. & Hartmann, R. W. in Cancer Drug Design and Discovery (ed. Neidle, S.) 319-356 (Academic Press, 2014).